During Wednesday’s trade, Shares of Facebook Inc (NASDAQ:FB), lost -1.85% to $104.52.
Facebook is changing the advertising policies for its Instant Articles platform, after publishers said restrictions made it too hard for them to generate revenue from content they posted to the social network’s new feature, according to WSJ
Facebook said it will now allow publishers to comprise more advertising in each article, and to sell Facebook-only ad campaigns to marketers if they wish.
Publishers will also have the option to highlight and link to specific content hosted on their own sites from the “related articles” section at the bottom of Instant Articles templates, counting branded or sponsored posts.
Michael Reckhow, Facebook’s Instant Articles product manager, said the company is making the tweaks in response to feedback it gleaned from publishers.
“We’re ongoing to listen to publishers about what they want from Instant Articles, and we’re going to continue to do this. This is one step forward but we will continue to listen,” Mr. Reckhow said.
Mr. Reckhow said that limitation was in place because Facebook wanted to avoid “confusion in the marketplace with different sales teams selling Facebook inventory,” but said it now believes advertisers grasp the difference between ads in Instant Articles and those appearing elsewhere across the social network. WSJ Report
Publishers were “leaving money on the table by under-serving ads,” Mr. Reckhow said.
On the other report, Facebook has lifted a ban that blocked material from Tsu.co, a small rival challenging the world’s largest social network’s financial dependence on free content shared by its 1.5 billion users, according to mercury news
The reversal comes a month after The Associated Press published a story airing concerns that Facebook might be abusing its power to thwart competition and stifle the concept advanced by Tsu that people should be paid for the stories and images that they post on social networks.
“We won in the court of public opinion,” Tsu CEO Sebastian Sobczak said Tuesday. “When you have something new and novel in the market like what we are doing, this kind of validation is extremely important. It feels like we just got a golden stamp of approval.”
Facebook decided Tsu’s payments represented a financial incentive for people to share links on its network, something the Menlo Park, California, company says it prohibits because it believes the practice pollutes its service with the digital rubbish known as “spam.” mercury news Report
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), declined -31.69% to $4.85, during its current trading session.
Aeterna Zentaris Inc. (AEZS) (AEZ.TO) declared the pricing of its formerly declared underwritten public offering (the “Offering”) of common shares and warrants with a public offering price of US$5.55 for one common share together with a warrant to purchase 0.7 of a common share for gross proceeds of US$16.65 million. A total of 3.0 million common shares and warrants to acquire 2.1 million common shares are predictable to be issued on closing of the Offering. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 330,000 common shares and/or warrants to purchase up to an additional 231,000 common shares, to cover over-allotments, if any.
Net proceeds from the Offering are predictable to be about US$15.0 million, after deducting underwriting commissions and discounts and other expenses related to the Offering. The Company intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, for the potential addition of commercialized products to the Company’s portfolio, and for general corporate purposes, for working capital and to fund negative cash flow.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Finally, Shares of Dow Chemical Co (NYSE:DOW), gain 10.04%, and is now trading at $56.02.
Stocks are heading mostly lower in midday trading as an early gain fades away, according to AP
If the market ends down Wednesday it would extend a slump into a third day.
Costco led a drop in consumer staples stocks after reporting weaker earnings than analysts were expecting.
Dow Chemical and DuPont rose sharply following reports that the two companies were talking about a combination.
Energy and materials companies moved higher together with the price of oil and other commodities.
The Standard & Poor’s 500 index lost four points, or 0.2 percent, to 2,059 as of 11:45 a.m. Eastern time. The Nasdaq composite gave up 44 points, or 0.9 percent, to 5,053.
The Dow Jones industrial average got a boost from DuPont. The 30-stock average raised 12 points, or 0.1 percent, to 17,581. AP Report
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments.